Supplementary Texts

Text S1: Processing of Rembrandt copy number data
We downloaded Affymetrix 100K SNP array data from Rembrandt (release 1.5.9) [1] , reconstructed hybridization images and performed stringent quality controls to remove all arrays with hybridization artifacts. We identified 78 tumor samples (16 AS II, 17 AS III, 45 GBM IV) and 8 blood reference samples that passed this quality check (Tab. S1). Next, we analyzed these data using R connected to a local installation of the GenePattern server [2] . The SNPFileCreator module was used to transform each array into a single-nucleotide polymorphism (SNP) file in combination with standard dChip normalization of each array against a global blood reference sample (Rembrandt-IDs: E09419 for Xba240 arrays and E10615 for Hind240 arrays). The obtained SNP files of tumor samples were further converted into log 2 -ratio copy number profiles under consideration of average blood sample reference measurements. All resulting tumor-specific copy number profiles were further segmented using circular binary segmentation (CBS) [3] to identify individual deletions and amplifications of chromosomal regions. We finally utilized the obtained segmentation profiles to determine corresponding gene copy number measurements for each individual gene in each individual tumor. In some cases, breakpoints occurred within genes and we then utilized the corresponding average log-ratio of involved segments to specify the copy of the affected gene.
Text S2: Lasso-based regulatory network inference
We considered gene-specific sub-network inference problems to learn a transcriptional regulatory network associated with the expression of molecular signature genes distinguishing PA I from AS II, AS III and GBM IV. Therefore, we focused on the expression levels of N = 1, 089 signature genes in our data set of in total D = 125 astrocytoma samples comprising 47 PA I, 16 AS II, 17 AS III and 45 GBM IV tumors. For each signature gene i ∈ {1, . . . , N }, we assumed that its expression level e id in an astrocytoma d ∈ {1, . . . , D} can be predicted by a linear combination e id = j∈TF\{i} a ji · e jd (1) of the expression levels e jd of transcriptional regulators j ∈ TF \ {i} that were part of the molecular signature that distinguishes PA I from AS II, AS III and GBM IV. Here, TF defines the subset of genes in the molecular signature that were annotated as TFs (151 of 1,089). The expression level e id of each gene i in an astrocytoma d is given by the log 2 -ratio of the expression level of gene i in astrocytoma d in comparison to the expression level of gene i in the corresponding average normal brain reference. The unknown parameters of this signature gene-specific linear model are given by a i := (a ji ) j∈TF\{i} . Each individual parameter a ji ∈ R quantifies the impact of the expression level of transcriptional regulator j on the expression level of signature gene i: (i) a ji < 0 specifies that TF j is a putative inhibitor of gene i,
(ii) a ji > 0 defines that TF j is a putative activator of gene i, and (iii) a ji = 0 means that no dependency between j and i exists.
We used lasso (least absolute shrinkage and selection operator) regression [4] to determine a sparse solution for the signature gene-specific linear model in Eq. (1). Lasso minimizes the residual sum of squares
of the measured expression e id of gene i and the model-based predicted expression of gene i under consideration of all astrocytomas in dependency of a fixed signature gene-specific complexity parameter λ i . The complexity parameter λ i determines the amount of shrinkage of the individual model parameters a ji toward zero, where larger values of λ i lead to greater shrinkage. This allows to select relevant transcriptional regulators, because irrelevant model parameters will be shrunken to zero. We used the R package glmnet [5] to determine an optimal signature gene-specific complexity parameter and corresponding optimal model parameters. We determined λ i by averaging the optimal complexity parameters (cv.glmnet: lambda.min) obtained from ten independent repeats of a ten-fold cross-validation across all astrocytomas. We then used this gene-specific complexity parameter λ i to compute the corresponding optimal model parameters considering all astrocytomas. We further determined the significance of model parameters when they first enter the lasso model in Eq. (2) using a recently developed significance test for lasso [6] . This provides an efficient way to get p-values instead of using computationally expensive permutation strategies. To realize this, we first computed the lasso solution paths for the active transcriptional regulators (model parameters in a * i that are unequal zero) with respect to all astrocytomas using the R package lars [7] . These results were further evaluated using the R package covTest [8] Glioma and control specimens were fixed in 10% formaldehyde and embedded in paraffin. Sections (4µm) were deparaffinized and antigen retrieval was performed. A Ventana Benchmark automated staining system was used for immunohistochemistry of Ang2 (anti-human Ang-2 antibody ((MAB 0983), 1:100 from R&D Biosciences, Minneapolis, MN, USA). For antigen retrieval, cell conditioning 1 (prediluted, Ventana Medical Systems) was used. After incubation with the primary and corresponding secondary antibody, the signal was detected with the Chromo DAB Map kit (Ventana Medical Systems) and with the IHC Ultra Map AP (Ventana Medical Systems) kit. Note that the Ang2 protein is encoded by the ANGPT2 gene (alias ANG2).
Endothelial cells are the source of Ang2 protein expression in both PA I and GBM IV
To assess the cellular source of genes significantly contributing to the clustering of PA I within the mesenchymal subgroup of glioblastoma, we exemplarily analyzed normal and neoplastic CNS tissue for Ang2 by immunohistochemistry (Fig. S4 ). Of note, normal white ( Fig. S4A ) and gray ( Fig. S4B ) matter were completely devoid of Ang2. In contrast, both PA I (Fig. S4C ) and GBM IV (Fig. S4F) showed prominent Ang2-positive endothelial cells in case that activated blood vessel were present, a feature that was largely absent in AS II (Fig. S4D ) and AS III (Fig. S4E ). This finding indicates that the significantly higher Angpt2 mRNA expression found in PA I and GBM IV is strongly related to the presence of vascular proliferation which -per definition -are only seen in those tumor entities while being absent in WHO grade II and III astrocytomas.
Text S4: Network validation based on independent glioma cohorts 1.4.1 Independent glioma gene expression data for regulatory network validation
We downloaded raw PA I expression data published in [9] from Gene Expression Omnibus (GSE5675) and normalized all microarrays using GCRMA [10] . This independent PA I cohort contained expression levels of 16,973 genes for 41 PA I tumor samples. We further downloaded processed gene expression data of brain lower grade gliomas and glioblastoma from The Cancer Genome Atlas (TCGA) data portal (https://tcga-data.nci.nih.gov/tcga/). The TCGA lower grade glioma cohort (TCGA LGG) comprised expression profiles of 465 patients measured on Agilent 244K Custom Gene Expression G4502A-07-3 microarrays. Each patient-specific expression profile contained 15,924 genes that were overlapping with the 16,973 genes contained in our basic astrocytoma data sets described in the main manuscript. The gene expression measurements were provided as log-ratios of tumor compared to a normal universal reference. The TCGA LGG cohort included 50 AS II and 104 AS III samples. The other samples were oligoastrocytomas (OAS II: 50, OAS III: 69), oligodendrogliomas (OD II 69, OD III: 92) and no clinical information was available for 41 samples. Similarly, the TCGA glioblastoma cohort (TCGA GBM: GBM IV) comprised expression profiles of 553 GBM IV patients measured on Agilent 244K Custom Gene Expression G4502A-07-1 or G4502A-07-2 microarrays. Each patient-specific expression profile comprised 14,213 genes that overlapped with the 16,973 genes in our basic astrocytoma data sets.
Network validation using independent glioma cohorts
We validated the predictive power of the obtained signature-specific regulatory network on independent data. Therefore, we utilized more than one thousand publicly available gene expression profiles from three independent brain tumor cohorts (41 PA I tumors from [9] , 465 low grade gliomas (including AS II and AS III) and 553 GBM IV tumors from TCGA). For each signature gene, we predicted its expression level in each of these public tumor expression profiles using the previously determined signature genespecific linear model with corresponding parameters derived from our astrocytoma training data set. We then computed the correlation between predicted and measured expression levels of each signature gene across all tumor samples for each validation cohort and observe significant shifts of each cohortspecific correlation distribution into the positive range ( for each validation cohort, Wilcoxon rank sum test). Thus, the derived regulatory network is also highly predictive for the vast majority of signature genes in independent brain tumors suggesting that the network includes relevant regulatory links.
Text S5: Comparison of motif search-based and gene expression-based
TF-target links
Motif search-based TF-target identification
We downloaded TF-binding site models from [11] and [12] for TFs included in the molecular signature distinguishing PA I from AS II, AS III and GBM IV. These models enabled us to compare predicted target genes of TFs in the transcriptional regulatory network to corresponding target genes of signature-specific TFs identified using motif search to determine the proportion of putative direct physical interactions in the network. Each TF-binding site model was represented by a specific position weight matrix (PWM) modeling the DNA-binding preferences of the TF. We obtained PWMs of 28 TFs from HOCOMOCO [11] and 37 TF-specific PWMs from JOLMA [12] . We further determined putative promoter sequences (DNA sequences 1,000 bp upstream of annotated transcription start sites) of all 1,089 molecular signature genes using the UCSC Genome Browser (upstream1000.fa.gz: hg19, GRCh37, downloaded April 2014). We next used FIMO (Find Individual Motif Occurrences) [13] to search for binding sites of each signaturespecific TF in the promoter sequences of all signature genes. For each TF, we provided its specific PWM and all promoter sequences of signature genes as input data to FIMO. FIMO reported by default all motif occurrences in promoter sequences with p-values less than 0.0001. This enabled us to determine putative target genes of each specific TF based on its DNA-binding preferences. We compared these independently derived TF target gene interactions with the corresponding target genes of the TF in our signature-specific transcriptional regulatory network. To realize this, we quantified the significance of the size of the overlap between both sets of target genes using Fisher's exact test.
Signature-specific TF-target validation
We further compared predicted target genes of TFs in the regulatory network to target genes predicted using motif search to evaluate the proportion of putative direct physical interactions in the regulatory network. Therefore, we considered binding site models of signature-specific TFs included in HOCO-MOCO [11] and JOLMA [12] and searched for occurrences of putative TF binding sites in promoter sequences 1,000 bp upstream of each signature gene using FIMO [13] . This allowed us to identify potential direct target genes that we compared with the corresponding target genes of the TF in the reg- 
